The putative role of the C1858T polymorphism of protein tyrosine phosphatase PTPN22 gene in autoimmunity

Elena Gianchecchi, Melania Palombi, Alessandra Fierabracci

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Autoimmune diseases represent a heterogeneous group of conditions whose incidence is increasing worldwide. This has stimulated studies on their etiopathogenesis, derived from a complex interaction between genetic and environmental factors, in order to improve prevention and treatment of these diseases.An increasing amount of epidemiologic investigations has associated the presence of the C1858T polymorphism in the protein tyrosine phosphatase non-receptor type 22 (PTPN22) gene to the onset of several autoimmune diseases including insulin-dependent diabetes mellitus (Type 1 diabetes).PTPN22 encodes for the lymphoid tyrosine phosphatase Lyp. This belongs to non-receptor-type protein tyrosine phosphatases involved in lymphocyte activation and differentiation. In humans, Lyp may have a role in the negative regulation of T cell receptor signaling. The single nucleotide polymorphism C1858T encodes for a more active phosphatase Lyp R620W. This has the ability to induce a higher negative regulation of T cell receptor signaling. Thus, C1858T could play an important role at the level of thymocyte polarization and escape of autoreactive T lymphocytes, through the positive selection of otherwise negatively selected autoimmune T cells.In this review we discuss the physiological role exerted by the PTPN22 gene and its encoded Lyp product in lymphocyte processes. We highlight the pathogenic significance of the C1858T PTPN22 polymorphism in human autoimmunity with special reference to Type 1 diabetes.Recently the genetic variation in PTPN22 was shown to induce altered function of T and B-lymphocytes. In particular BCR signaling defects and alterations in the B cell compartment were reported in T1D patients. We finally speculate on the possible development of novel therapeutic treatments in human autoimmunity aiming to selectively target the variant Lyp protein in autoreactive T and B lymphocytes.

Original languageEnglish
Pages (from-to)717-725
Number of pages9
JournalAutoimmunity Reviews
Volume12
Issue number7
DOIs
Publication statusPublished - May 2013

Fingerprint

Non-Receptor Type 22 Protein Tyrosine Phosphatase
Protein Tyrosine Phosphatases
Autoimmunity
Type 1 Diabetes Mellitus
Genes
B-Lymphocytes
T-Cell Antigen Receptor
T-Lymphocytes
Autoimmune Diseases
Non-Receptor Protein Tyrosine Phosphatases
Thymocytes
Lymphocyte Activation
Phosphoric Monoester Hydrolases
Single Nucleotide Polymorphism
Tyrosine
Therapeutics
Lymphocytes
Incidence

Keywords

  • Autoimmunity etiopathogenesis
  • B lymphocytes
  • Candidate autoimmune genes
  • Lyp protein
  • Prevention-treatment
  • PTPN22 gene
  • T lymphocytes

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

The putative role of the C1858T polymorphism of protein tyrosine phosphatase PTPN22 gene in autoimmunity. / Gianchecchi, Elena; Palombi, Melania; Fierabracci, Alessandra.

In: Autoimmunity Reviews, Vol. 12, No. 7, 05.2013, p. 717-725.

Research output: Contribution to journalArticle

@article{ee3b4fcb73534b1087201680e72105f7,
title = "The putative role of the C1858T polymorphism of protein tyrosine phosphatase PTPN22 gene in autoimmunity",
abstract = "Autoimmune diseases represent a heterogeneous group of conditions whose incidence is increasing worldwide. This has stimulated studies on their etiopathogenesis, derived from a complex interaction between genetic and environmental factors, in order to improve prevention and treatment of these diseases.An increasing amount of epidemiologic investigations has associated the presence of the C1858T polymorphism in the protein tyrosine phosphatase non-receptor type 22 (PTPN22) gene to the onset of several autoimmune diseases including insulin-dependent diabetes mellitus (Type 1 diabetes).PTPN22 encodes for the lymphoid tyrosine phosphatase Lyp. This belongs to non-receptor-type protein tyrosine phosphatases involved in lymphocyte activation and differentiation. In humans, Lyp may have a role in the negative regulation of T cell receptor signaling. The single nucleotide polymorphism C1858T encodes for a more active phosphatase Lyp R620W. This has the ability to induce a higher negative regulation of T cell receptor signaling. Thus, C1858T could play an important role at the level of thymocyte polarization and escape of autoreactive T lymphocytes, through the positive selection of otherwise negatively selected autoimmune T cells.In this review we discuss the physiological role exerted by the PTPN22 gene and its encoded Lyp product in lymphocyte processes. We highlight the pathogenic significance of the C1858T PTPN22 polymorphism in human autoimmunity with special reference to Type 1 diabetes.Recently the genetic variation in PTPN22 was shown to induce altered function of T and B-lymphocytes. In particular BCR signaling defects and alterations in the B cell compartment were reported in T1D patients. We finally speculate on the possible development of novel therapeutic treatments in human autoimmunity aiming to selectively target the variant Lyp protein in autoreactive T and B lymphocytes.",
keywords = "Autoimmunity etiopathogenesis, B lymphocytes, Candidate autoimmune genes, Lyp protein, Prevention-treatment, PTPN22 gene, T lymphocytes",
author = "Elena Gianchecchi and Melania Palombi and Alessandra Fierabracci",
year = "2013",
month = "5",
doi = "10.1016/j.autrev.2012.12.003",
language = "English",
volume = "12",
pages = "717--725",
journal = "Autoimmunity Reviews",
issn = "1568-9972",
publisher = "Elsevier",
number = "7",

}

TY - JOUR

T1 - The putative role of the C1858T polymorphism of protein tyrosine phosphatase PTPN22 gene in autoimmunity

AU - Gianchecchi, Elena

AU - Palombi, Melania

AU - Fierabracci, Alessandra

PY - 2013/5

Y1 - 2013/5

N2 - Autoimmune diseases represent a heterogeneous group of conditions whose incidence is increasing worldwide. This has stimulated studies on their etiopathogenesis, derived from a complex interaction between genetic and environmental factors, in order to improve prevention and treatment of these diseases.An increasing amount of epidemiologic investigations has associated the presence of the C1858T polymorphism in the protein tyrosine phosphatase non-receptor type 22 (PTPN22) gene to the onset of several autoimmune diseases including insulin-dependent diabetes mellitus (Type 1 diabetes).PTPN22 encodes for the lymphoid tyrosine phosphatase Lyp. This belongs to non-receptor-type protein tyrosine phosphatases involved in lymphocyte activation and differentiation. In humans, Lyp may have a role in the negative regulation of T cell receptor signaling. The single nucleotide polymorphism C1858T encodes for a more active phosphatase Lyp R620W. This has the ability to induce a higher negative regulation of T cell receptor signaling. Thus, C1858T could play an important role at the level of thymocyte polarization and escape of autoreactive T lymphocytes, through the positive selection of otherwise negatively selected autoimmune T cells.In this review we discuss the physiological role exerted by the PTPN22 gene and its encoded Lyp product in lymphocyte processes. We highlight the pathogenic significance of the C1858T PTPN22 polymorphism in human autoimmunity with special reference to Type 1 diabetes.Recently the genetic variation in PTPN22 was shown to induce altered function of T and B-lymphocytes. In particular BCR signaling defects and alterations in the B cell compartment were reported in T1D patients. We finally speculate on the possible development of novel therapeutic treatments in human autoimmunity aiming to selectively target the variant Lyp protein in autoreactive T and B lymphocytes.

AB - Autoimmune diseases represent a heterogeneous group of conditions whose incidence is increasing worldwide. This has stimulated studies on their etiopathogenesis, derived from a complex interaction between genetic and environmental factors, in order to improve prevention and treatment of these diseases.An increasing amount of epidemiologic investigations has associated the presence of the C1858T polymorphism in the protein tyrosine phosphatase non-receptor type 22 (PTPN22) gene to the onset of several autoimmune diseases including insulin-dependent diabetes mellitus (Type 1 diabetes).PTPN22 encodes for the lymphoid tyrosine phosphatase Lyp. This belongs to non-receptor-type protein tyrosine phosphatases involved in lymphocyte activation and differentiation. In humans, Lyp may have a role in the negative regulation of T cell receptor signaling. The single nucleotide polymorphism C1858T encodes for a more active phosphatase Lyp R620W. This has the ability to induce a higher negative regulation of T cell receptor signaling. Thus, C1858T could play an important role at the level of thymocyte polarization and escape of autoreactive T lymphocytes, through the positive selection of otherwise negatively selected autoimmune T cells.In this review we discuss the physiological role exerted by the PTPN22 gene and its encoded Lyp product in lymphocyte processes. We highlight the pathogenic significance of the C1858T PTPN22 polymorphism in human autoimmunity with special reference to Type 1 diabetes.Recently the genetic variation in PTPN22 was shown to induce altered function of T and B-lymphocytes. In particular BCR signaling defects and alterations in the B cell compartment were reported in T1D patients. We finally speculate on the possible development of novel therapeutic treatments in human autoimmunity aiming to selectively target the variant Lyp protein in autoreactive T and B lymphocytes.

KW - Autoimmunity etiopathogenesis

KW - B lymphocytes

KW - Candidate autoimmune genes

KW - Lyp protein

KW - Prevention-treatment

KW - PTPN22 gene

KW - T lymphocytes

UR - http://www.scopus.com/inward/record.url?scp=84877815750&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877815750&partnerID=8YFLogxK

U2 - 10.1016/j.autrev.2012.12.003

DO - 10.1016/j.autrev.2012.12.003

M3 - Article

VL - 12

SP - 717

EP - 725

JO - Autoimmunity Reviews

JF - Autoimmunity Reviews

SN - 1568-9972

IS - 7

ER -